Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GD2 CAR-T (Guangzhou FineImmune)
- Development stage
- Preclinical
- Lead developer
- Guangzhou FineImmune Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
GD2 CAR-T is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Guangzhou FineImmune Biotechnology. It is designed to target the disialoganglioside GD2, a surface antigen highly expressed in neuroblastoma and other neuroectodermal tumors. The therapy involves genetically modifying a patient's own T cells to express a CAR specific for GD2, enabling them to recognize and eliminate GD2-positive tumor cells. It is currently part of the company's SUPER CAR-T/TCR-T platform, which focuses on developing high-affinity cell therapies for solid tumors.
- Other names
- GD2-targeted CAR-TGD-2-targeted CAR-TGD 2-targeted CAR-TGD2 CAR-T cell therapyGD-2 CAR-T cell therapyGD 2 CAR-T cell therapy
02
Targets
GD2
Beyond the preview
Go deeper on GD2 CAR-T (Guangzhou FineImmune).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GD2 CAR-T (Guangzhou FineImmune).